Bayer's Rally Faces Its Sternest Test: A Split Analyst Field and a September Courtroom Verdict

Bayer shares rally 33% but face a pivotal Sept 14 glyphosate ruling; analysts split between 46-63.50 euro targets.

The shares have climbed roughly a third since January, yet the debate over where Bayer goes from here has rarely been more fractured. On one side sit five major investment houses that have rushed to lift their price targets into the 60-to-63.50-euro range; on the other, a single prominent skeptic whose 46-euro target stands nearly 18 euros below the most bullish call. With the stock changing hands near 49 euros, the market has effectively parked itself between the two camps, unwilling to commit to either narrative.

That gap between Jefferies' "Hold" rating and the cluster of "Buy" and "Overweight" recommendations from Goldman Sachs, UBS, JPMorgan, Deutsche Bank and DZ Bank is striking for a DAX constituent of Bayer's size. It reflects not a disagreement over the underlying facts, but over how heavily those facts should be weighted — a split that has become the defining feature of the current trading phase.

The Legal Calendar Now Overlays the Valuation Debate

Complicating the picture is a date that could reshape the entire risk assessment: September 14, when a Missouri court is scheduled to rule on final approval of the multi-billion-dollar class-action settlement covering US glyphosate litigation. The hearing was originally set for August 19 but was pushed back, giving investors a concrete new marker in a legal saga that has weighed on the company for years.

The settlement's fate is arguably the single most important variable in the near term — more consequential than operational issues such as drought pressure in the agriculture division or questions about capital structure. A green light would remove a persistent overhang that has capped the share price for years; a rejection or further delay would likely send the risk premium sharply higher.

What the Bulls Are Betting On

The optimists' case rests on a convergence of factors. The pharma division delivered a recent catalyst when Japan's health ministry granted marketing approval for Hyrnuo, a lung cancer treatment, adding to momentum in the sector. Management has also reaffirmed its focus on accelerated debt reduction following the second quarter, and market reports suggest the company is embracing a "Dynamic Shared Ownership" model aimed at fostering greater entrepreneurial accountability across divisions.

The technical picture lends some support to the bullish view. The stock trades roughly 18 percent above its 200-day average and sits about 87 percent above the low struck on November 7, 2025. The gap to the 50-day moving average of 47.29 euros stands at around 3.7 percent, suggesting the short-term uptrend remains intact — though a separate reading puts the stock about 2.8 percent above that same line, a discrepancy that underscores how quickly the technicals can shift.

The Bear Case: A Warning That Shouldn't Be Dismissed

Jefferies' caution deserves more than a shrug. The 46-euro target implies meaningful downside from current levels, and the sheer distance between the most optimistic and most pessimistic forecasts signals genuine uncertainty about how sustainable the underlying earnings improvements really are. Historically, divergent calls on Bayer have often flagged unresolved risk factors that later proved material.

The bearish scenario also has operational hooks. The extreme summer drought of 2026 is viewed by analysts as a serious test for Crop Science, even if the same observers see an offsetting opportunity in drought-resistant seed technology. Meanwhile, some financial media voices continue to push for a structural breakup of the group into Crop Science, Pharma and Consumer Health — a narrative the company explicitly ruled out roughly three weeks ago, but one that nonetheless keeps questions about the future corporate structure alive. With 30-day volatility running at 24 percent, the stock remains vulnerable to sharp swings in either direction.

A Market Suspended Between Two Outcomes

For now, the shares sit roughly ten percent below their 52-week high of 53.86 euros, having gained 31 percent since the start of the year. That advance reflects a considerable amount of pre-emptive trust from the market — trust that the September court date will either vindicate or expose as premature.

The near-term path appears binary. As long as expectations of judicial approval hold, the stock is likely to defend its relative strength against its moving averages. Should the hearing produce another postponement or an adverse ruling, the market would probably repricing Bayer's risk profile quickly. The September 14 hearing is thus the next genuine test of whether the year's rally rests on solid ground or on credit the company has yet to earn. Until then, the shares remain a mirror of the unusually wide expectations gap among professional observers — a setup that carries both opportunity and risk in equal measure.